Treatment and education reduce the severity of schistosomiasis periportal fibrosis

Silva, Paula Carolina Valença; Leal, Tallita V.; Domingues, Ana Lúcia Coutinho

doi:10.1590/0037-8682-0110-2013

Cited by 17 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sanitation and community health education in addition to chemotherapeutic intervention are measures that effectively contribute to the control and/or elimination of Schistosoma infection in several endemic areas and the resolution or attenuation of progressive forms of disease at individual level [10,46,47]. However, the determination of the effects of these measures, in particular, drug intervention, still presents as a challenge (Table 1).…”

Section: Assessment Of Morbidity and Drug Response In Community And Imentioning

confidence: 99%

Schistosomiasis – Updating Technologies and Diagnostic Approaches in Surveillance Strategies and Clinical Management

Cavalcanti¹,

Peralta²

2015

An Overview of Tropical Diseases

View full text Add to dashboard Cite

Schistosoma infection is a poverty-related parasitic infection, being the second most important neglected tropical disease in the world after malaria. Schistosomiasis is caused by five distinct Schistosoma species distributed in tropical and subtropical areas. But, imported cases can also be seen in non-endemic areas. Human populations acquire infection after exposure to contaminated water collections. Schistosoma infection falls on a large spectrum of clinical manifestations that ranges from absence of signs and symptoms to severe forms of disease. Although morbidity and mortality have been reduced along the years after use of mass drug administration (MDA) in endemic areas, large populations are still at risk of disability-related outcomes on daily basis. Recently, a great deal of debate has been done over two main issues in schistosomiasis management in endemic and non-endemic areas: how to accurately diagnosis Schistosoma infections pre and post-therapy in addition to assess morbidity level. Adoption of promising new diagnostic tools and development of new markers of disease progression might change the current scenario by improving schistosomiasis clinical management in both community and institutional settings.

show abstract

Section: Assessment Of Morbidity and Drug Response In Community And Imentioning

confidence: 99%

Schistosomiasis – Updating Technologies and Diagnostic Approaches in Surveillance Strategies and Clinical Management

Cavalcanti¹,

Peralta²

2015

An Overview of Tropical Diseases

View full text Add to dashboard Cite

show abstract

“…Schistosomiasis is considered the second most prevalent human parasitic disease and remains a serious public health problem because of the morbidity caused by the progression of the disease . Currently, it is estimated that over 207 million people are infected in 77 countries around the world, including Africa, the Middle East, the Caribbean, Brazil, Venezuela and Suriname .…”

Section: Introductionmentioning

confidence: 99%

“…The main immunopathology resulting from the disease is characterized by chronic granulomatous inflammation , which consists of a delayed hypersensitivity reaction mediated by CD4 + T cells directed against the parasites’ eggs which are retained in the intrahepatic branches of the portal vein and/or are deposited in the liver parenchyma . When this granulomatous reaction is not controlled, the liver becomes fibrotic.…”

Section: Introductionmentioning

confidence: 99%

Receptor Antagonist of IL‐13 Exerts a Potential Negative Regulation During Early Infection of Human Schistosomiasis

Al¹,

Wg³

et al. 2016

Scand J Immunol

View full text Add to dashboard Cite

The pathology of schistosomiasis is associated with the formation of granulomas, and this process is associated with liver fibrosis. Studies indicate that Th1 cytokines reduce fibrosis in schistosomiasis, while Th2 cytokines play a part in the progression of fibrosis, and IL-13 has a critical role in this process. The IL-13Rα2 receptor, known as a 'receptor antagonist' binds with high affinity to IL-13, and studies have identified that this plays a part in reducing fibrosis and the size of granulomas. The objective of this study was to evaluate the function of IL-13Rα2 and cellular immune response in hepatic fibrosis. A negative correlation between IL-13Rα2 and IL-13 was found, suggesting an increase in cytokine in early fibrosis. Initially, a negative correlation between IFN-γ and IL-13 was found in patients without fibrosis, and subsequently, this correlation was found to be positive in patients with severe fibrosis, thereby highlighting a new mechanism for regulating the progress of periportal fibrosis. There was a positive correlation between the profiles of Th1 and Th2 cytokines, suggesting the presence of both responses, thus regulating the disease. The results contribute to a better understanding of the immune mechanisms that control the process of hepatic fibrogenesis in schistosomiasis in humans.

show abstract

“…Sex, age, parasite load, alcohol consumption, exposure frequency, exposure duration, and other factors may affect the development and severity of PPF (3) . On the other hand, specifi c treatment may also contribute to reducing infection levels and consequently improve the clinical picture of hepatosplenomegaly and PPF (4) (5) .…”

mentioning

confidence: 99%

There is no evident correlation between interleukin-10 gene polymorphisms and periportal fibrosis regression after specific treatment

Silva

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:We evaluated the associations between interleukin-10 (IL-10) gene polymorphisms -G1082A/-C819T/-C592A and periportal fi brosis regression after specifi c treatment for schistosomiasis. Methods: This retrospective cohort study involved 125 Brazilian patients infected with Schistosomiasis mansoni, who were followed up for 2 years after specifi c treatment to estimate the probability of periportal fi brosis regression. Results: There was no evidence of associations between IL-10 polymorphisms and periportal fi brosis regression after treatment. Conclusions: There was no evidence of associations between gene promoter polymorphisms of IL-10 and the regression of periportal fi brosis in this Brazilian population.

show abstract

Treatment and education reduce the severity of schistosomiasis periportal fibrosis

Cited by 17 publications

References 17 publications

Schistosomiasis – Updating Technologies and Diagnostic Approaches in Surveillance Strategies and Clinical Management

Schistosomiasis – Updating Technologies and Diagnostic Approaches in Surveillance Strategies and Clinical Management

Receptor Antagonist of IL‐13 Exerts a Potential Negative Regulation During Early Infection of Human Schistosomiasis

There is no evident correlation between interleukin-10 gene polymorphisms and periportal fibrosis regression after specific treatment

Contact Info

Product

Resources

About